Overview

• Investor firms including Rosen, Johnson Fistel, Portnoy, Glancy Prongay & Murray, Bragar Eagel & Squire, and Faruqi & Faruqi are urging shareholders to seek lead-plaintiff status by October 21, 2025.
• The putative class covers purchases of Nutex securities from August 8, 2024 through August 14, 2025, with a case filed in the U.S. District Court for the Southern District of Texas.
• Complaints allege a third‑party vendor, HaloMD, secured lucrative arbitration outcomes through a coordinated scheme that inflated Nutex’s arbitration-driven revenues.
• Plaintiffs also claim Nutex overstated remediation of internal-control weaknesses and misclassified certain stock-based compensation as equity, contributing to delayed SEC filings.
• Shares fell about 10% after Blue Orca’s July 22, 2025 report and about 16% after the August 14 filing delay; Nutex previously said it strongly disagreed with the short-seller’s allegations, and no class has been certified.